Stem cell research is one of the most innovative research methods being used in modern society. Continue reading →

Visiongain Reports Ltd Visiongain has published a new report entitled Mesenchymal Stem Cells Market 2022-2032. It includes profiles of Mesenchymal Stem Cells Market and Forecasts Market Segment by Type {Product (Cell & Cell Lines, Kits Media & Reagents, Others), Services}, Market segment by Source (Bone Marrow, Adipose Tissue, Cord Blood, fallopian Tube, Fetal Liver, Lung, Peripheral Blood, Other Sources), Market Segment by Indication (Bone & Cartilage Repair, cardiovascular Disease, Cancer, GvHD, Inflammatory & Immunological Diseases, Liver Diseases, Other Diseases), Market Segment by Application (Disease Modelling, Drug Discovery & Development, Stem Cell Banking, Tissue Engineering, Toxicology Studies, Other Applications) plus COVID-19 Impact Analysis and Recovery Pattern Analysis (V-shaped, W-shaped, U-shaped, L-shaped), Profiles of Leading Companies, Region and Country. The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032. Continue reading →

Calgary, Alberta--(Newsfile Corp. - September 27, 2022) - Hemostemix Inc. Continue reading →

Key Highlights: Melbourne, Australia; 26 September 2022: Cynata Therapeutics Limited (ASX: CYP or Cynata), a clinical-stage biotechnology company specialising in cell therapeutics, is delighted to announce that the Australian Government National Health and Medical Research Council (NHMRC) has awarded a grant of approximately $1 million under the NHMRC 2021 MRFF Cardiovascular Health Mission, to fund a major preclinical research project to investigate Cynatas Cymerus MSCs as a treatment for IHD. The project will be led by Dr Shiang (Max) Lim (Head, Cardiac Regeneration Laboratory, St Vincent's Institute of Medical Research, Melbourne). It will also involve a number of other leading institutions, including the University of Adelaide, Baker Heart and Diabetes Institute, the University of South Australia, Duke-National University of Singapore Medical School, the University of Arizona, Monash University, Westmead Institute for Medical Research, and hearts4heart Continue reading →

The US Supreme Courts Dobbs decision striking down the constitutional right to abortion (which has sparked a renewed debate over when human life begins) all but guarantees that the issue of setting research limits on fetal tissue testing will be contested in the US courts and in the court of public opinion. Many of those with ethical doubts look at the issue through an idiosyncratic lens. The discord in their analytical approaches is troubling and provides an unreliable basis to address the issue. Continue reading →

BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that Vertex has concluded discussions with the U.S. Food and Drug Administration (FDA), and the FDA granted exagamglogene autotemcel (exa-cel) a rolling review for the potential treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Vertex will submit its biologics licensing application (BLA) for exa-cel for rolling review, beginning in November 2022 and expects to complete the submission by the end of Q1 2023 Continue reading →

Melhem Solh, MD, discusses his research on post-transplant outcomes of patients with TP53-mutant acute myeloid leukemia and myelodysplastic syndrome. Melhem Solh, MD, medical director for the Cellular Therapy Program at Northside Hospital, discusses his research on post-transplant outcomes of patients with TP53-mutant acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Investigators, including Solh, examined 30 patients to evaluate overall survival (OS), relapse and non-relapse mortality, and disease-free survival (DFS) in patients with AML or MDS with a TP53 mutation and who had underwent an allogeneic hematopoietic stem cell transplant for this indication Continue reading →

JACKSON CENTER, PA / ACCESSWIRE / September 27, 2022 / Halberd Corporation (OTC PINK:HALB) entered into a strategic alliance with AI Longevity, Inc. and Stem of Hope to form a strategic alliance as a wholly owned subsidiary of Halberd Corporation named "ExtendalifeTM." The mission will be to develop treatments intended to increase longevity and develop successful Alzheimer's Disease and Cancer treatments using the combined patented and patent-pending technologies of the alliance member companies Continue reading →

Los Angeles, USA: A recent report published by Verified Market Research, titled [Global Stem Cell Assay Market, History and Forecasts for 2022-2029, data broken down by manufacturers, key regions, types and applications], contains an in-depth analysis of the Global Stem Cell Assay Market. The research report is divided in such a way as to highlight the key areas of the market and give the reader a complete picture. The report examines various aspects of the Stem Cell Assay market, such as its opportunities to explore its driving forces and limitations, market size, market segment analysis, regional prospects, key players and the competitive environment. Continue reading →

Researchers design CAR T cells engineered with a dominant negative TGF receptor that can break through solid tumor defenses iStock When developing chimeric antigen receptor (CAR) T cell therapy, researchers take T cells from a patients blood and engineer them to target specific antigens presented on cancer cells. Continue reading →